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1,2 Mibefradil had been approved for the treatment of angina pectoris and hypertension by the FDA in 1997. According to accumulation of new findings on T-type calcium channels, it has been reported that T-type calcium channels play crucial roles in the control of pain which are caused by hyperexitable neurons. 3 The role of T-type calcium channels in pain has been addressed using specific genetic modulation of T-type calcium channel isoforms. In the case of Ca V 3.1 knockout (α 1G −/− ) mice, it was observed that, after L5 spinal nerve ligation, spontaneous pain responses were reduced and a threshold for paw withdrawal was increased in response to mechanical stimulation.
4 Ca V 3.2 antisense treatment resulted in major anti-nociceptive and anti-hyperalgesic effect, suggesting that Ca V 3.2 plays a major pronociceptive role in acute and chronic pain states.
5
Together, the results of these two studies suggest that blocking T-type calcium channels should reduce nociceptive pain and neuropathic pain.
Herein we report design, synthesis and biological evaluation of novel isophthalamide derivatives as T-type calcium channel blockers. Recently, we designed 1,3-dioxoisoindoline-5-carboxamide derivatives with assistance of a pharmacophore model generated and synthesized those compounds, of which the biological results were reported ( Figure 1) . 6 Based on the previous SAR (structure-activity relationship) study, new isophthalamide derivatives 2 were designed, synthesized and biologically evaluated (Figure 1) .
The isophthalamide derivatives were synthesized in 3 steps starting from isophthalic acid monoester 3 (Scheme 1). Isophthalic acid monoester 3 underwent amide coupling with various benzyl amines by treatment with N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBt) to give compounds 4 in 70-82% yields. The compounds 4 were hydrolyzed to give the corresponding benzoic acids 5, which were transformed into the desired isophthalamide derivatives 2 in 22-68% yields by coupling with various 3-R 2 -propylamines in the presence of EDCI and HOBt.
Total 26 isophthalamide derivatives 2a-z, thus prepared, were biologically evaluated against α 1G (Ca V 3.1) T-type calcium channel in HEK293 cells which stably express both T-type calcium channel Ca V 3.1 and potassium channel Kir2.1.
7 All the synthesized compounds were screened by fluorescence-based HTS (high throughput screening) FDSS600 assay,
8 and the %-inhibitions of Ca 2+ current measured at 10 μM concentration of the isophthalamide derivatives are summarized in Table 1 . In general, compounds with m-Cl (2g-2l, Table 1 ) or p-Cl (2m-2r, Table 1 ) group as R 1 showed higher activity than the corresponding compounds with H (2a-2f, Table 1 ), m-Me (2s-2v, Table 1 ) and p-Me (2w-2z, Table 1) substituents. Among the compounds tested, compounds with high %-inhibition (2i, 2l, 2m, 2n and 2o, Table 1 ) were selected for the patch-clamp assay which is more accurate and more sensitive. 9 The patch-clamp assay is a very time-consuming process because it measures %-inhibition of Ca 2+ current with a single cell at each concentration with one compound, and thus, only 5 compounds were selected for accurate screening. The selected compounds were found to be active with IC 50 values between 2.66 μM to 13.53 μM, and among those, compound 2l showed activity against α 1G T-type calcium channel with an IC 50 value of 2.66 μM, which is comparable to that of mibefradil.
Based on the results of the SAR study described above, it is clear that the bulky R 2 substituent increases the biological activity of the corresponding compound. Thus, compound 2l with octahydroquinolin-1-(2H)-yl group is more active than 2i with 2-ehtylpiperidin-1-yl group. Also, the compound 2o with 2-ehtylpiperidin-1-yl group is more active than the compound 2n with 2-mehtylpiperidin-1-yl group, which, in turn, is more active than the compound 2m with piperidin-1-yl group.
In summary, the SAR study of isophthalamides 2 with R 1 and R 2 substituents revealed that the bulky R 2 is favored for high biological activity, which provides valuable insights into the design and optimization of novel α 1G T-type calcium channel blockers.
